Inhaled corticosteroids for chronic obstructive pulmonary disease

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 18, 2013, Pages 2489-2499

  Cazzola, Mario ^a   Rogliani, Paola ^a   Novelli, Lucia ^a   Matera, Maria Gabriella ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Chronic obstructive pulmonary disease; Emerging inhaled corticosteroids; Guidelines; Inhaled corticosteroids

Indexed keywords

ANTIBIOTIC AGENT; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; DEXAMETHASONE; FLUTICASONE; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; FORMOTEROL; FORMOTEROL FUMARATE; INDACATEROL; IPRATROPIUM BROMIDE; METHYLPREDNISOLONE; MOMETASONE FUROATE; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE; VILANTEROL;

ACETYLCHOLINE RELEASE; ADD ON THERAPY; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CATARACT; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE EFFECTIVENESS; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY POWDER INHALER; FORCED EXPIRATORY VOLUME; GLAUCOMA; HUMAN; HYPERGLYCEMIA; LUNG FUNCTION; MAINTENANCE THERAPY; META ANALYSIS; META ANALYSIS (TOPIC); METERED DOSE INHALER; MONOTHERAPY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT ALLERGY; REVIEW; SKIN BRUISING; SMOOTH MUSCLE; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; LUNG; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84887905775     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.848856     Document Type: Review

References (85)

1. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011;378:1015-26
2. Spurzem JR, Rennard SI. Pathogenesis of COPD. Semin Respir Crit Care Med 2005;26:142-53
3. Cazzola M, Page CP, Calzetta L, Matera MG. Emerging anti-inflammatory strategies for COPD. Eur Respir J 2012;40:724-41
4. Raissy HH, Kelly HW, Harkins M, Szefler SJ. Inhaled corticosteroids in lung diseases. Am J Respir Crit Care Med 2013;187:798-803
5. Walters JAE, Gibson PG, Wood-Baker R, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2009;CD001288
6. Ceviker Y, Sayiner A. Comparison of two systemic steroid regimens for the treatment of COPD exacerbations. Pulm Pharmacol Ther 2013; published online 18 March; doi:10.1016/j.pupt.2013.03.004
7. Calverley PM. The role of corticosteroids in chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2005;26:235-45
8. Barnes PJ. Inhaled corticosteroids in COPD: A controversy. Respiration 2010;80:89-95
9. Jen R, Rennard SI, Sin DD. Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: A systematic review and meta-Analysis. Int J Chron Obstruct Pulmon Dis 2012;7:587-95
10. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: From lung function to biomarkers. Eur Respir J 2008;31:416-68
11. Soriano JB, Sin DD, Zhang X, et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 2007;131:682-9
12. Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;7:CD002991
13. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: Results from the TORCH study. Am J Respir Crit Care Med 2008;178:332-8
14. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: A randomized trial. Ann Intern Med 2009;151:517-27
15. Kunz LI, Strebus J, Budulac SE, et al. Inhaled steroids modulate extracellular matrix composition in bronchial biopsies of COPD patients: A randomized, controlled trial. PLoS One 2013;8:e63430
16. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005;60:992-7
17. Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Inhaled corticosteroids vs placebo for preventing COPD exacerbations: A systematic review and metaregression of randomized controlled trials. Chest 2010;137:318-25
18. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ 2000;320:1297-303
19. Van Der Valk P, Monninkhof E, Van Der Palen J, et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: The COPE study. Am J Respir Crit Care Med 2002;166:1358-63
20. Glaab T, Taube C. Effects of inhaled corticosteroids in stable chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2011;24:15-22
21. Zervas E, Samitas K, Gaga M, et al. Inhaled corticosteroids in COPD: Pros and cons. Curr Drug Targets 2013;14:192-224
22. Yang N, Ray DW, Matthews LC. Current concepts in glucocorticoid resistance. Steroids 2012;77:1041-9
23. Barnes PJ. Glucocorticosteroids: Current and future directions. Br J Pharmacol 2011;163:29-43
24. Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2013;131:636-45
25. Gamble E, Grootendorst DC, Hattotuwa K, et al. Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: A pooled analysis. Eur Respir J 2007;30:467-71
26. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176:162-6
27. Singh S, Amin AV, Loke YK. Long-Term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: A meta-Analysis. Arch Intern Med 2009;169:219-29
28. Thornton Snider J, Luna Y, Wong KS, et al. Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD. Curr Med Res Opin 2012;28:1959-67
29. Yawn BP, Li Y, Tian H, et al. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: A retrospective claims data analysis. Int J Chron Obstruct Pulmon Dis 2013;8:295-304
30. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: A meta-Analysis of individual patient data. Lancet 2009;374:712-19
31. National Institute for Health and Clinical Excellence. CG101 Chronic Obstructive Pulmonary Disease (update): Full guideline 23 June 2010. Available from: Http://www.nice.org [Last accessed 28 July 2013]
32. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: A clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011;155:179-91
33. Global initiative for chronic Obstructive Lung Disease.Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2013. Available from: Http://www.goldcopd.org/ [Last accessed 27 July 2013]
34. Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish COPD Guidelines (GesEPOC): Pharmacological treatment of stable COPD. Arch Bronconeumol 2012;48:247-57
35. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-19
36. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89
37. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/ fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144-9
38. Sobieraj DM, White CM, Coleman CI. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: A meta-Analysis. Clin Ther 2008;30:1416-25
39. Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-Acting beta-Agonists and inhaled corticosteroids vs. long-Acting beta-Agonists monotherapy for stable COPD. Chest 2009;136:1029-38
40. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-Acting beta2-Agonist in one inhaler versus long-Acting beta2-Agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;9:CD006829
41. Dong YH, Lin HH, Shau WY, et al. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: Systematic review and mixed treatment comparison meta-Analysis of randomised controlled trials. Thorax 2013;68:48-56
42. Cazzola M, Dahl R. Inhaled combination therapy with long-Acting beta2-Agonists and corticosteroids in stable COPD. Chest 2004;126:220-37
43. Rossios C, To Y, Osoata G, et al. Corticosteroid insensitivity is reversed by formoterol via phosphoinositide-3-kinase inhibition. Br J Pharmacol 2012;167:775-86
44. Adner M, Larsson B, Safholm J, et al. Budesonide prevents cytokine-induced decrease of the relaxant responses to formoterol and terbutaline, but not to salmeterol, in mouse trachea. J Pharmacol Exp Ther 2010;333:273-80
45. Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012;64:450-504
46. Emala CW, Clancy J, Hirshman CA. Glucocorticoid treatment decreases muscarinic receptor expression in canine airway smooth muscle. Am J Physiol 1997;272:L745-51
47. Jacoby DB, Yost BL, Kumaravel B, et al. Glucocorticoid treatment increases inhibitory m2 muscarinic receptor expression and function in the airways. Am J Respir Cell Mol Biol 2001;24:485-91
48. Moreno L, Jacoby DB, Fryer AD. Dexamethasone prevents virus-induced hyperresponsiveness via multiple mechanisms. Am J Physiol Lung Cell Mol Physiol 2003;285:L451-5
49. Hodder R, Kesten S, Menjoge S, Viel K. Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis 2007;2:157-67
50. Scherr A, Schafroth Torok S, Jochmann A, et al. Response to add-on inhaled corticosteroids in COPD based on airway hyperresponsiveness to mannitol. Chest 2012;142:919-26
51. Um SW, Yoo CG, Kim YW, et al. The combination of tiotropium and budesonide in the treatment of chronic obstructive pulmonary disease. J Korean Med Sci 2007;22:839-45
52. Choi J, Na J, Kim Y. The effect of tiotropium and inhaled corticosteroid combination therapy in chronic obstructive pulmonary disease (COPD) and chronic obstructive bronchial asthma (COBA) associated with irreversible pulmonary function. Am J Respir Crit Care Med 2007;175: A130
53. Lee TA, Wilke C, Joo M, et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch Intern Med 2009;169:1403-10
54. Rodrigo GJ, Plaza V, Castro-Rodríguez JA. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: A systematic review. Pulm Pharmacol Ther 2012;25:40-7
55. Calverley PM, Rennard S, Nelson HS, et al. One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res 2008;9:73
56. Tashkin DP, Doherty DE, Kerwin E, et al. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: Results from a 52-week Phase III trial. Int J Chron Obstruct Pulmon Dis 2012;7:43-55
57. Doherty DE, Tashkin DP, Kerwin E, et al. Effects of mometasone furoate/ formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): Results from a 52-week Phase III trial in subjects with moderate-To-very severe COPD. Int J Chron Obstruct Pulmon Dis 2012;7:57-71
58. Tashkin DP, Doherty DE, Kerwin E, et al. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: Findings from pooled analysis of two randomized, 52-week placebo-controlled trials. Int J Chron Obstruct Pulmon Dis 2012;7:73-86
59. Cazzola M, Rogliani P, Segreti A, Matera MG. An update on bronchodilators in Phase I and II clinical trials. Expert Opin Investig Drugs 2012;21:1489-501
60. Singas E, Karpel JP. Profile of ciclesonide for the maintenance treatment of asthma. TherClin Risk Manag 2011;7:351-8
61. Berger WE. Ciclesonide. a novel inhaled corticosteroid for the treatment of persistent asthma. Therapy 2005;2:167-78
62. Colice GL. The newly developed inhaled corticosteroid ciclesonide for the treatment of asthma. Expert Opin Pharmacother 2006;7:2107-17
63. Rossios C, To Y, To M, et al. Long-Acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur J Pharmacol 2011;670:244-51
64. Allen A, Bareille PJ, Rousell VM. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet 2013;52:37-42
65. Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 mg) improves lung function in COPD: A randomised trial. Resp Med 2013;107:550-9
66. Lotvall J, Bakke PS, Bjermer L, et al. Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/ vilanterol in a single inhaler given once daily in COPD: A placebo-controlled randomised trial. BMJ Open 2012;2:e000370
67. Boscia JA, Pudi KK, Zvarich MT, et al. Effect of once-daily fluticasone furoate/vilanterol on 24-h pulmonary function in patients with chronic obstructive pulmonary disease: A randomized, three-way, incomplete block, crossover study. Clin Ther 2012;34:1655-66
68. Kerwin EM, Scott-Wilson C, Sanford L, et al. A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD. Respir Med 2013;107:560-9
69. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: Two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med 2013;1:210-23
70. FDA News Release. FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease. Available from: Http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ ucm351664.htm [Last accessed 8 August 2013]
71. Nadeem NJ, Taylor SJ, Eldridge SM. Withdrawal of inhaled corticosteroids in individuals with COPD: A systematic review and comment on trial methodology. Respir Res 2011;12:107
72. Cazzola M, Segreti A, Bettoncelli G, et al. Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. Prim Care Respir J 2011;20:291-8
73. Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med 2012;106:989-97
74. Franssen FM, Spruit MA, Wouters EF. Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2011;6:493-501
75. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: Analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009;10:59
76. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: A randomized trial. Ann Intern Med 2009;15:517-27
77. Agusti A, Calverley P, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;11:122
78. Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: The future of COPD. Am J Respir Crit Care Med 2010;182:598-604
79. Miravitlles M, Soler-Cataluña JJ, Calle M, et al. A new approach to grading and treating COPD based on clinical phenotypes: Summary of the Spanish COPD guidelines (GesEPOC). Prim Care Respir J 2013;22:117-21
80. Miravitlles M, Soler-Cataluña JJ, Calle M, Soriano JB. Treatment of COPD by clinical phenotypes: Putting old evidence into clinical practice. Eur Respir J 2013;41:1252-6
81. Disantostefano RL, Li H, Rubin DB, Stempel DA. Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. BMJ Open 2013;3:e001838
82. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: The case against. EurRespir J 2009;34:13-16
83. Vanfleteren LE, Kocks JW, Stone IS, et al. Moving from the Oslerian paradigm to the post-genomic era: Are asthma and COPD outdated terms? Thorax 2013; published online on 22 June; doi: 10.1136/thoraxjnl-2013-203602
84. Cazzola M, Segreti A, Rogliani P. Comparative effectiveness of drugs for chronic obstructive pulmonary disease. Drugs Today (Barc) 2012;48:785-94
85. Telenga ED, Kerstjens HA, Postma DS, et al. Inhaled corticosteroids in chronic obstructive pulmonary disease: A review. Expert Opin Pharmacother 2010;11:405-21